Ampliphi Biosciences Corp (APHB)

0.88
0.01 1.20
AMEX : Health Care
Prev Close 0.89
Open 0.93
Day Low/High 0.82 / 0.93
52 Wk Low/High 1.45 / 13.50
Volume 232.22K
Avg Volume 634.70K
Exchange AMEX
Shares Outstanding 6.63M
Market Cap 5.50M
EPS -330.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AmpliPhi Biosciences To Present At 7th Annual LD Micro Invitational Conference On June 6

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that CEO M.

AmpliPhi Biosciences Reports First Quarter 2017 Financial Results And Provides Business Highlights

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces financial results for the quarter ended March 31,...

AmpliPhi Biosciences To Hold Business Update Conference Call On May 15

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that management will hold a business update...

AmpliPhi Biosciences Announces Closing Of Public Offering

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the closing of its...

AmpliPhi Biosciences Announces Pricing Of $10.4 Million Underwritten Public Offering Of Common Stock And Common Warrants

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the pricing of an...

AmpliPhi Biosciences Announces A New Strategic Emphasis On Personalized Therapies For Serious Or Life-Threatening Antibiotic-Resistant Infections

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the field of bacteriophage technology, announces a new strategic emphasis on precisely targeted and personalized medicines designed to address the surging...

AmpliPhi Biosciences Announces Presentation Of Personalized Bacteriophage Therapy Case Study For Life-Threatening Antibiotic-Resistant Infection At Scientific Conference

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for drug-resistant bacterial infections using bacteriophage technology, announces that a case study highlighting the...

AmpliPhi Biosciences Announces Positive Feedback From FDA On Phase 2 Development Proposal

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for drug-resistant bacterial infections using bacteriophage technology, announces that the U.

AmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that its board of directors has approved...

AmpliPhi Biosciences Announces Presentations Of Clinical And Preclinical Data From Studies With Its Bacteriophage Technology At Two Scientific Conferences

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that data from its investigational...

AmpliPhi Biosciences Reports 2016 Fourth-Quarter And Full-Year Results And Provides Corporate Highlights

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced financial results for the quarter and...

AmpliPhi Biosciences To Present At The 29th Annual ROTH Investor Conference

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that CEO M.

AmpliPhi Biosciences Establishes Scientific Advisory Board And Appoints Dr. Timothy Lu Of MIT And Broad Institute As SAB Chairman

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based therapies to treat drug-resistant bacterial infections, announces the formation of its Scientific Advisory Board...

AmpliPhi Biosciences To Present At The 19th Annual BIO CEO And Investor Conference

AmpliPhi Biosciences Corporation (NYSE MKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that CEO M.

AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky As Senior Vice President And Chief Operating Officer

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the appointment of Igor P.

Renowned Sinus Surgeon Dr. Peter-John Wormald Comments On AmpliPhi Biosciences' Favorable Phase 1 Results Of AB-SA01 In Chronic Rhinosinusitis Patients

Renowned Sinus Surgeon Dr. Peter-John Wormald Comments On AmpliPhi Biosciences' Favorable Phase 1 Results Of AB-SA01 In Chronic Rhinosinusitis Patients

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that Peter-John Wormald, MD, Professor...

AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial Of AB-SA01 In Chronic Rhinosinusitis Patients

AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial Of AB-SA01 In Chronic Rhinosinusitis Patients

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today reported final results from its Phase 1 trial of...

AmpliPhi Biosciences Announces Pricing Of Public Offering Of Common Stock And Warrants

AmpliPhi Biosciences Announces Pricing Of Public Offering Of Common Stock And Warrants

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced the pricing of an underwritten public...

AmpliPhi Biosciences Announces Settlement Of Pending Lawsuit

AmpliPhi Biosciences Announces Settlement Of Pending Lawsuit

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced the settlement of its...

AmpliPhi Biosciences Reports Third Quarter 2016 Financial Results And Provides Corporate Update

AmpliPhi Biosciences Reports Third Quarter 2016 Financial Results And Provides Corporate Update

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced financial results for the...

AmpliPhi Biosciences Granted Small And Medium Enterprise Status By European Medicines Agency

AmpliPhi Biosciences Granted Small And Medium Enterprise Status By European Medicines Agency

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced that it has been granted...

AmpliPhi Biosciences Announces Favorable Topline Safety And Tolerability Results From Its Phase 1 Trial In Patients With Chronic Rhinosinusitis

AmpliPhi Biosciences Announces Favorable Topline Safety And Tolerability Results From Its Phase 1 Trial In Patients With Chronic Rhinosinusitis

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced topline results from its...

AmpliPhi Biosciences Appoints Dr. Carrie-Lynn Langlais Furr As Vice President Of Regulatory Affairs And Program Management

AmpliPhi Biosciences Appoints Dr. Carrie-Lynn Langlais Furr As Vice President Of Regulatory Affairs And Program Management

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced that Carrie-Lynn Langlais...

AmpliPhi Biosciences Provides Update On Phase 1 Trial In Chronic Rhinosinusitis Patients

AmpliPhi Biosciences Provides Update On Phase 1 Trial In Chronic Rhinosinusitis Patients

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced an update on the progress of its ongoing...

AmpliPhi Biosciences Announces Topline Results From Its Phase 1 Phage Therapy Trial Conducted In The United States

AmpliPhi Biosciences Announces Topline Results From Its Phase 1 Phage Therapy Trial Conducted In The United States

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced topline data from a Phase 1 trial to...

AmpliPhi Biosciences To Participate In Upcoming Conferences

AmpliPhi Biosciences To Participate In Upcoming Conferences

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that company management will...

AmpliPhi Biosciences' Bacteriophage Cocktail Shown To Prevent C. Difficile Biofilm Formation And Reduce Colonization

AmpliPhi Biosciences' Bacteriophage Cocktail Shown To Prevent C. Difficile Biofilm Formation And Reduce Colonization

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announced the publication of data from a preclinical...